Julie Laurin
Corporate Officer/Principal at Alethia Biotherapeutics, Inc.
Julie Laurin active positions
| Companies | Position | Start | End |
|---|---|---|---|
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - | - |
Career history of Julie Laurin
Former positions of Julie Laurin
| Companies | Position | Start | End |
|---|---|---|---|
| DAVIDSTEA INC. | Corporate Officer/Principal | 31/05/2019 | 30/04/2020 |
| BELLUS HEALTH | Corporate Officer/Principal | - | - |
Training of Julie Laurin
| University of Montréal | Doctorate Degree |
Statistics
International
| Canada | 5 |
Operational
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
| Consumer Non-Durables | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| DAVIDSTEA INC. | Consumer Non-Durables |
| Private companies | 2 |
|---|---|
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
- Stock Market
- Insiders
- Julie Laurin
- Experience